A phase II, randomized, double-blind, parallel groups study to assess the efficacy and safety of Nimodipine 20 mg + Betahistine 16 mg versus Placebo + Betahistine 16 mg in the treatment of vertigo

Registry ID

EUCTR2013-005122-33

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

MDM S.p.A.

Start date

2014-01-22

Last update

2026-08-16

Conditions

• Vertigo

Summary

To evaluate the efficacy of Nimodipine 20 mg + Betahistine 16 mg (b.i.d) for the treatment of vertigo, compared to Betahistine 16 mg (b.i.d), as assessed by the Dizziness Handicap Inventory (DHI) after 4 weeks of treatment

Locations

• , , Italy

Related clinical trials

• Evaluation of Nystagmus Examination Using Wearable AR Glasses in Vertigo Patients
• Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
• Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
• Diagnostic Aid for Vertigo Patients
• Reducing Vertigo Associated With MRI Machines
• Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

View on source registry